<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drug dosing for treatment of drug-susceptible tuberculosis (rifapentine-moxifloxacin-based regimen) in patients ≥12 years</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drug dosing for treatment of drug-susceptible tuberculosis (rifapentine-moxifloxacin-based regimen) in patients ≥12 years</h1>
<div class="graphic"><div class="figure"><div class="ttl">Drug dosing for treatment of drug-susceptible tuberculosis (rifapentine-moxifloxacin-based regimen) in patients ≥12 years</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33.33%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Drug</td> <td class="subtitle1">Preparations</td> <td class="subtitle1">Daily dose<br/> (administered as a single dose)</td> </tr> <tr class="divider_bottom"> <td>Isoniazid*</td> <td>Oral: <ul class="decimal_heading"> <li>Tablet: 100 mg, 300 mg</li> <li>Oral solution: 50 mg/5 mL</li> </ul> IM, IV: <ul class="decimal_heading"> <li>Solution for injection: 100 mg/mL</li> </ul> </td> <td>300 mg</td> </tr> <tr class="divider_bottom"> <td>Rifapentine</td> <td>Oral: <ul class="decimal_heading"> <li>Tablet: 150 mg</li> </ul> </td> <td>1.2 g</td> </tr> <tr class="divider_bottom"> <td>Moxifloxacin</td> <td>Oral: <ul class="decimal_heading"> <li>Tablet: 400 mg</li> </ul> IV: <ul class="decimal_heading"> <li>Solution for injection: 400 mg/250 mL</li> </ul> </td> <td>400 mg</td> </tr> <tr> <td>Pyrazinamide</td> <td>Oral: <ul class="decimal_heading"> <li>Tablet: 500 mg</li> </ul> </td> <td>Dosing based on patient weight:<sup>¶</sup> <ul class="decimal_heading"> <li>≥40 to 55 kg: 1 g</li> <li>≥55 to 75 kg: 1.5 g</li> <li>&gt;75 kg: 2 g</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li>The regimen summarized in this table is intended for patients with age ≥12 years, weight ≥40 kg, and CrCl ≥30 mL/min.</li>
<li>Antituberculous agents are used in multidrug combination regimens. The shortened 4-month regimen consists of an intensive phase (8 weeks of <a href="https://alltopics.utdlab.com/contents/rifapentine-drug-information?topicRef=8015&amp;source=see_link" target="_blank">rifapentine</a>, <a href="https://alltopics.utdlab.com/contents/isoniazid-drug-information?topicRef=8015&amp;source=see_link" target="_blank">isoniazid</a>, <a href="https://alltopics.utdlab.com/contents/pyrazinamide-drug-information?topicRef=8015&amp;source=see_link" target="_blank">pyrazinamide</a>, and <a href="https://alltopics.utdlab.com/contents/moxifloxacin-drug-information?topicRef=8015&amp;source=see_link" target="_blank">moxifloxacin</a> administered once daily), followed by a continuation phase (9 weeks of rifapentine, isoniazid, and moxifloxacin administered once daily). Refer to the UpToDate clinical topic for discussion.</li>
</ul></div><div class="graphic_footnotes"><p>IM: intramuscular; IV: intravenous; CrCl: creatinine clearance.</p>
<p>* Pyridoxine (vitamin B6) 25 to 50 mg/day is given with isoniazid to individuals at risk for neuropathy (eg, pregnant women, individuals with HIV infection, diabetes, alcoholism, malnutrition, chronic renal failure, or advanced age). For patients with peripheral neuropathy, experts recommend increasing pyridoxine dose to 100 mg/day.</p>
	
	¶ Based on actual body weight<sup>[1]</sup>. Some experts dose based on estimated lean body weight<sup>[2]</sup>. A calculator for estimating lean body weight is available separately in UpToDate.</div><div class="graphic_reference">Data from:
	<ol>
<li>Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med 2021; 384:1705.</li>
<li>Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American clinical practice guidelines: Treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016; 63:e147.</li>
</ol></div><div id="graphicVersion">Graphic 131747 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
